19 related articles for article (PubMed ID: 34732430)
1. Real-world use of enzalutamide in men with nonmetastatic castration-resistant prostate cancer in Japan.
Yokomizo A; Yonese J; Egawa S; Fukuhara H; Uemura H; Nishimura K; Nagata M; Saito A; Lee T; Yamaguchi S; Nonomura N
Int J Clin Oncol; 2022 Feb; 27(2):418-426. PubMed ID: 34779962
[TBL] [Abstract][Full Text] [Related]
2. Lactate Dehydrogenase Is a Serum Prognostic Factor in Clinically Regional Lymph Node-positive Prostate Cancer.
Blas L; Shiota M; Yamada S; Ieiri K; Nagakawa S; Tsukahara S; Matsumoto T; Kashiwagi E; Takeuchi A; Inokuchi J; Shiga KI; Yokomizo A; Eto M
Anticancer Res; 2021 Aug; 41(8):3885-3889. PubMed ID: 34281850
[TBL] [Abstract][Full Text] [Related]
3. Assessment of lower urinary symptom flare with overactive bladder symptom score and International Prostate Symptom Score in patients treated with iodine-125 implant brachytherapy: long-term follow-up experience at a single institute.
Miyake M; Tanaka N; Asakawa I; Hori S; Morizawa Y; Tatsumi Y; Nakai Y; Inoue T; Anai S; Torimoto K; Aoki K; Hasegawa M; Fujii T; Konishi N; Fujimoto K
BMC Urol; 2017 Aug; 17(1):62. PubMed ID: 28806948
[TBL] [Abstract][Full Text] [Related]
4. The prognosis and the impact of radiotherapy in clinically regional lymph node-positive prostate cancer: Which patients are candidates for local therapy with radiation?
Ieiri K; Shiota M; Kashiwagi E; Takeuchi A; Takahashi R; Inokuchi J; Iwai H; Shiga KI; Yokomizo A; Yoshitake T; Shioyama Y; Ishigami K; Terashima H; Eto M
Urol Oncol; 2020 Dec; 38(12):931.e1-931.e7. PubMed ID: 32900626
[TBL] [Abstract][Full Text] [Related]
5. Assessment of lower urinary tract symptoms in men by international prostate symptom score and core lower urinary tract symptom score.
Fujimura T; Kume H; Nishimatsu H; Sugihara T; Nomiya A; Tsurumaki Y; Miyazaki H; Suzuki M; Fukuhara H; Enomoto Y; Homma Y
BJU Int; 2012 May; 109(10):1512-6. PubMed ID: 21883834
[TBL] [Abstract][Full Text] [Related]
6. Associations of Clinical and Dosimetric Parameters with Urinary Toxicities after Prostate Brachytherapy: A Long-Term Single-Institution Experience.
Ito M; Makita C; Mori T; Takano H; Kumano T; Matsuo M; Iinuma K; Kawase M; Nakane K; Nakano M; Koie T
Curr Oncol; 2023 Jun; 30(6):5680-5689. PubMed ID: 37366909
[TBL] [Abstract][Full Text] [Related]
7. Prognostic Value of Lower Tract Urinary Symptoms in Clinically Regional Lymph Node-positive Prostate Cancer.
Blas L; Ieiri K; Shiota M; Nagakawa S; Tsukahara S; Matsumoto T; Kashiwagi E; Takeuchi A; Inokuchi J; Shiga KI; Yokomizo A; Eto M
Anticancer Res; 2021 Nov; 41(11):5593-5598. PubMed ID: 34732430
[TBL] [Abstract][Full Text] [Related]
8. EAU Guidelines on the Assessment of Non-neurogenic Male Lower Urinary Tract Symptoms including Benign Prostatic Obstruction.
Gratzke C; Bachmann A; Descazeaud A; Drake MJ; Madersbacher S; Mamoulakis C; Oelke M; Tikkinen KAO; Gravas S
Eur Urol; 2015 Jun; 67(6):1099-1109. PubMed ID: 25613154
[TBL] [Abstract][Full Text] [Related]
9. 10-year survival of a patient with metastatic prostate cancer: Case report and literature review.
Krpina K; Markić D; Rahelić D; Ahel J; Rubinić N; Španjol J
Arch Ital Urol Androl; 2015 Sep; 87(3):252-3. PubMed ID: 26428652
[TBL] [Abstract][Full Text] [Related]
10.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
11.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
